Supported cancer types

IndiTreat® is for cancer therapy selection

With IndiTreat®, you can test different panels of drugs and drug combinations on microtumors derived from individual patients to identify resistance and sensitivity.

IndiTreat® CE IVD Colorectal Cancer Test

A method of determining which drugs offer the most suitable therapies for different patients with stage III–IV colorectal cancer, this test can be used before:

  • Postoperative adjuvant therapy
  • Neoadjuvant therapy
  • 1st and 2nd line therapy of metastatic disease
  • Therapy of end-stage metastatic patients
  • HIPEC (hyperthermic intraperitoneal chemotherapy)

IndiTreat® Ovarian Cancer Test

This test indicates which panels offer the most suitable therapies for different patients with ovarian cancer. Multi-center clinical validation trials are ongoing. This test is used before:

  • Postoperative adjuvant therapy
  • Neoadjuvant therapy
  • Therapy of recurrence regardless of previous platinum response
  • Selection of the most effective PARP-inhibitor in BRCA-mt patients
  • Selection of BRCA-wt patients who shall benefit from PARP-inhibition
  • Therapy of end-stage patients

IndiTreat® Pancreatic Cancer Test

A method of determining which drugs offer the most suitable therapies for different patients with pancreatic cancer. Multi-center clinical validation trials are ongoing. This test is used before:

  • Postoperative adjuvant therapy
  • Neoadjuvant therapy if a pancreatic biopsy is feasible
  • 1st and 2nd line palliative therapy

Want to know more?

Want to know more?

Contact us

Please contact 2cureX for more information

Email: info@2cureX.com
Phone: +45 22115399
Web: www.IndiTreat.com

Upcoming events

August 28, 2021

Interim Report Q2 2021

View previous reports

November 25, 2021

Interim Report Q3 2021

View previous reports

February 24, 2022

Year-End Report 2021

View previous reports

Key benefits of IndiTreat

  • Tumor resistance
    Predict tumor resistance and sensitivity to cancer drugs
  • Right cancer treatment
    Select the most appropriate treatment, in accordance with guidelines or off-label
  • Better patient outcome
    Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Help chemo-naïve CRC patients
    Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Help late-stage CRC patients
    Identify the most effective treatment in late-stage colorectal cancer patients
  • Functional precision medicine
    Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs